References
- Janssens K, Vanhoenacker F, Bonduelle M, et al. Camurati-Engelmann disease: review of the clinical, radiological, and molecular data of 24 families and implications for diagnosis and treatment. J Med Genet. 2006;43:1–11.
- Kinoshita A, Saito T, Tomita H, et al. Domain-specific mutations in TGFB1 result in Camurati-Engelmann disease. Nat Genet. 2000;26:19–20.
- Collet C, Laplanche JL, de Vernejoul MC. Camurati-Engelmann disease with obesity in a newly identified family carrying a missense p.Arg156Cys mutation in the TGFB1 gene. Am J Med Genet. 2013;161A:2074–2077.
- Iba K, Takada J, Kamasaki H, et al. A significant improvement in lower limb pain after treatment with alendronate in two cases of Camurati-Engelmann disease. J Bone Miner Metab. 2008;26:107–109.
- Baroncelli GI, Ferretti E, Pini CM, et al. Significant improvement of clinical symptoms, bone lesions, and bone turnover after long-term zoledronic acid treatment in patients with a severe form of Camurati-Engelmann disease. Mol Syndromol. 2017;8:294–302.
- Castro GRW, Appenzeller S, Marques-Neto JF, et al. Camurati-Engelmann disease: failure of response to bisphosphonates. Report of two cases. Clin Rheumatol. 2005;24:398–401.
- Inaoka T, Shuke N, Sato J, et al. Scintigraphic evaluation of pamidronate and corticosteroid therapy in a patient with progressive diaphyseal dysplasia (Camurati-Engelmann disease). Clin Nucl Med. 2001;26:680–682.
- Diédhiou D, Cuny T, Sarr A, et al. Efficacy and safety of denosumab for the treatment of osteoporosis: a systematic review. Ann Endocrinol (Paris). 2015;76:650–657.
- Kumaki D, Nakamura Y, Suzuki T, et al. Efficacy of denosumab for osteoporosis in two patients with adult-onset Still’s disease denosumab efficacy in osteoporotic Still’s disease patients. JCM. 2018;7:63.
- Uehara M, Nakamura Y, Takahashi J, et al. Efficacy of denosumab therapy for neurofibromatosis type 1 with osteoporosis and history of fractures: a case report. Ther Clin Risk Manag. 2018;14:1243–1246.
- Isobe F, Nakamura Y, Suzuki T, et al. Effects of denosumab on osteoporosis in three cases with anorexia nervosa and a review of the literature. Mod Rheumatol Case Rep. 2018;2:104–106.
- Uehara M, Nakamura Y, Takahashi J, et al. Efficacy of denosumab for osteoporosis in three female patients with osteogenesis imperfecta. Tohoku J Exp Med. 2017;242:115–120.
- Iqbal J, Sun L, Zaidi M. Coupling bone degradation to formation. Nat Med. 2009;15:729–731.
- Vasikaran S, Eastell R, Bruyère O, et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int. 2011;22:391–420.
- Hernández MV, Peris P, Guañabens N, et al. Biochemical markers of bone turnover in Camurati-Engelmann disease: a report on four cases in one family. Calcif Tissue Int. 1997;61:48–51.